ObsEva Files Second Quarter 2022 Financial Statements
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
Originally posted here:
ObsEva Files Second Quarter 2022 Financial Statements
Category Archives: Global News Feed
Cannabis Mitoviruses: An Introduction and State of Knowledge
VANCOUVER, British Columbia, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Segra International Corp. (“Segra”), an agriculture technology company is pleased to announce the publishing of a landmark white paper addressing the recent widespread identification of mitoviruses in cannabis cultivars.
Follow this link:
Cannabis Mitoviruses: An Introduction and State of Knowledge
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that it has granted equity inducement awards to three new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on August 16, 2022, in accordance with Nasdaq Listing Rule 5635(c)(4).
Link:
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Avicanna Announces Closing of Strategic Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS
More:
Avicanna Announces Closing of Strategic Private Placement
Plus Therapeutics Awarded $17.6 Million from State of Texas
Funding from the Cancer Prevention and Research Institute of Texas (CPRIT), the second largest global public funder of cancer research, will support the majority of the development costs of 186RNL for leptomeningeal metastases.
See the article here:
Plus Therapeutics Awarded $17.6 Million from State of Texas
Junshi Biosciences Announces Acceptance of Supplemental Application for Additional Indications of Adalimumab Injection
-- Additional indications: treatment for Crohn’s disease, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis and pediatric Crohn’s disease
See the original post:
Junshi Biosciences Announces Acceptance of Supplemental Application for Additional Indications of Adalimumab Injection
Valneva Provides Update on IXIARO® Supply Contract with U.S. Department of Defense
Saint Herblain (France), August 18, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) a specialty vaccine company, today announced that the U.S. Department of Defense (DoD) has decided not to exercise the second option year of the contract1 to supply Valneva’s Japanese encephalitis (JE) vaccine IXIARO®.
Read more:
Valneva Provides Update on IXIARO® Supply Contract with U.S. Department of Defense
Addex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate Update
Ad Hoc Announcement Pursuant to Art. 53 LR
Visit link:
Addex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate Update
Ultimovacs Expands High Dose Cohort Size in TENDU Phase I Prostate Cancer Trial after Safety Review
Oslo, 18 August 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, has completed treatment of three patients at the highest dose cohort in the phase I TENDU trial without any safety concerns. Based on these results, the company plans to enroll up to three additional patients at the highest dose level.
Read the original:
Ultimovacs Expands High Dose Cohort Size in TENDU Phase I Prostate Cancer Trial after Safety Review
Collaboration and Licensing Agreement
DXS INTERNATIONAL PLC
Continued here:
Collaboration and Licensing Agreement